Xilio Therapeutics Raises $50 Million Through Public Offering
Xilio Therapeutics, Inc. (NASDAQ: XLO), a pioneering biotechnology company based in Waltham, Massachusetts, has just announced an exciting development in its journey towards innovating cancer treatments. The company recently priced a public offering designed to raise $50 million through the sale of various types of warrants, aimed at enhancing its research and product development.
Details of the Public Offering
The offering comprises pre-funded warrants for the purchase of 66,676,000 shares of common stock, alongside a combination of Series A, Series B, and Series C warrants, each allowing purchase of similar amounts of common shares. The combined offering price for an individual unit of pre-funded warrant, Series A, Series B, and Series C warrant has been set at $0.7499, ensuring investors receive a valuable opportunity as they embark on this venture with Xilio Therapeutics.
Warrant Exercise and Expiration Details
The pre-funded warrants will be immediately exercisable and can be converted until fully utilized. Series A warrants can be exercised starting December 1, 2025, contingent upon the stock price reaching $1.50 for five consecutive trading days, making the investment more appealing for those watching market trends. Similarly, Series B and Series C warrants provide a structured timeline for exercise, potentially contributing to greater financial flexibility for investors.
Expected Impact of the Offering
The anticipated gross proceeds from this public offering are expected to bolster Xilio's pipeline of treatments, which focus on tumor-activated immuno-oncology therapies. These therapies aim to enhance efficacy while reducing systemic side effects, representing a groundbreaking step in cancer care.
Future Prospects and Company Goals
The funds raised from this offering intend to further propel Xilio's research into its innovative therapies and improve working capital. By focusing on localizing anti-tumor activity, Xilio's approach strives to change the landscape of cancer treatment, improving patient outcomes significantly.
Partnership and Underwriting
Leerink Partners has taken on the role of sole bookrunner for this public offering, signaling confidence in Xilio's strategic initiatives and market potential. This collaboration is expected to support a robust financial foundation for Xilio Therapeutics as it continues its mission.
Registration and Compliance
Additionally, Xilio has maintained transparency and regulatory compliance, having established a shelf registration statement with the Securities and Exchange Commission (SEC). This allows for smooth processing of the securities connected to this offering, ensuring investor confidence is upheld.
About Xilio Therapeutics
Xilio Therapeutics stands at the forefront of biotechnology, channeling its energy into the discovery and development of tumor-activated immuno-oncology therapies. The objective is to create treatments that significantly improve the lives of cancer patients while minimizing the typical adverse effects associated with existing therapies. By leveraging an exclusive platform, Xilio is advancing its pipeline focused on innovative tumor-activated molecules.
Frequently Asked Questions
What is the total amount Xilio Therapeutics aims to raise?
The company aims to raise approximately $50 million through this public offering.
What types of securities are included in the offering?
The offering includes pre-funded warrants and Series A, B, and C warrants for purchasing common stock.
Who is managing the public offering?
Leerink Partners is serving as the sole bookrunner for this public offering.
What will the raised funds be used for?
The proceeds from the offering will be used to advance the development of Xilio's product candidates and for general corporate purposes.
What is the status of SEC registration for this offering?
Xilio has an effective shelf registration statement with the SEC to facilitate the offering of its securities.
